Compass Therapeutics, Inc. (NASDAQ:CMPX) Stock Rated "Moderate Buy" by Sell-Side Brokerages

Key Points

• Compass Therapeutics received a “Moderate Buy” consensus rating from 17 analysts: 12 buys, one strong buy, three holds and one sell. The average 12-month price target is $10.25.
• CMPX opened at $0.76, near its 52-week low of $0.73 and well below its $6.88 high. The company recently reported a quarterly loss of $0.13 per share, missing estimates by $0.02.
• Institutional investors own 68.43% of the company, with BlackRock and Palo Alto Investors among those establishing new positions. Compass is developing antibody-based cancer treatments, including its lead candidate CTX-471.

Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the seventeen brokerages that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $10.25.

CMPX has been the subject of a number of analyst reports. Citigroup restated a "market outperform" rating on shares of Compass Therapeutics in a research report on Wednesday, September 23rd. LADENBURG THALM/SH SH initiated coverage on shares of Compass Therapeutics in a research note on Wednesday, July 1st. They set a "buy" rating and a $5.00 price objective for the company. Wedbush set a $4.00 target price on shares of Compass Therapeutics in a report on Wednesday, September 23rd. Citizens Jmp lowered their target price on shares of Compass Therapeutics to $4.00 and set a "market outperform" rating on the stock in a research note on Wednesday, September 23rd. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Compass Therapeutics in a research note on Thursday, October 15th.

Compass Therapeutics Stock Performance

NASDAQ CMPX opened at $0.76 on Thursday. Compass Therapeutics has a 52-week low of $0.73 and a 52-week high of $6.88. The company has a 50-day simple moving average of $1.53 and a 200 day simple moving average of $3.27. The company has a market capitalization of $136.92 million, a PE ratio of -1.90 and a beta of 1.02.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.02). As a group, analysts forecast that Compass Therapeutics will post -0.47 EPS for the current fiscal year.

Institutional Investors Weigh In On Compass Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. purchased a new position in Compass Therapeutics during the second quarter worth about $24,707,000. Palo Alto Investors LP bought a new position in Compass Therapeutics in the 2nd quarter worth about $12,771,670. Squarepoint Ops LLC increased its stake in Compass Therapeutics by 1,906.9% in the 2nd quarter. Squarepoint Ops LLC now owns 1,007,507 shares of the company's stock worth $2,206,000 after acquiring an additional 957,305 shares during the last quarter. Seven Fleet Capital Management LP increased its stake in Compass Therapeutics by 65.4% in the 1st quarter. Seven Fleet Capital Management LP now owns 940,538 shares of the company's stock worth $4,975,000 after acquiring an additional 371,791 shares during the last quarter. Finally, Bank of America Corp DE raised its holdings in shares of Compass Therapeutics by 224.9% in the 1st quarter. Bank of America Corp DE now owns 865,613 shares of the company's stock valued at $4,579,000 after acquiring an additional 599,179 shares in the last quarter. Hedge funds and other institutional investors own 68.43% of the company's stock.

About Compass Therapeutics

Compass Therapeutics is a clinical-stage biotechnology company focused on developing antibody-based medicines for cancer. The company's research is centered on therapies designed to activate and direct the immune system against tumor cells, with the goal of improving immune responses in patients with cancer.

Its lead product candidate, CTX-471, is a fully human monoclonal antibody designed to activate CD137, also known as 4-1BB. CD137 is a co-stimulatory receptor found on immune cells, including T cells and natural killer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.